PARIS, FRANCE, October 27, 2015 – HiFiBiO SAS announced today that the company’s next generation antibody discovery platform will be presented at the Seventh Annual PEGS Europe 2015 Protein and Antibody Engineering Summit, Nov. 2-6 in Lisbon, Portugal. The presentation, by William S. Somers, Ph.D., Vice President, Global Biotherapeutic Technologies at Pfizer Inc., will be on Tuesday, Nov 3 at 09:10 (WET).
Deep Microfluidic Screening for Discovery of Rare Antibodies with Optimal Properties
Pfizer is in a collaboration with HiFiBiO to establish a next generation microfluidic platform for antibody discovery that is allowing us to screen very large numbers of B-cells from humans and immunized animals for molecules that possess properties of interest. The massive throughput of the instrument and information rich assays allow Pfizer to identify rare antibodies that have both the biological activity of interest and favorable manufacturing properties.
HiFiBiO’s platform uses single cell-based screening of entire antibody-secreting B cell populations along with bar coded next generation sequencing and rapid DNA synthesis to identify multiple leads and enable the development of potential optimized antibody candidates. The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. Learn more at www.hifibio.com.